Koenraad Mertens

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 3 EPO patents. Top assignees: Stichting Sanquin Bloedvoorziening, Sanquin Blood Supply Foundation, Novo Nordisk A/s. Active years: 1999-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Koenraad Mertens. Retrieved from https://idiyas.com/inventor/koenraad-mertens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 50.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 108(Granted Patents)

Location History:

Amsterdam, NL (2018)
Leiden, NL (1999 - 2021)

Company Filing History:

5 out of 28

Stichting Sanquin Bloedvoorziening

patents

3 out of 3

Sanquin Blood Supply Foundation

Stiching Centraal Laboratorium Van De Bloedtransfusiedienst Van Nederlandse Rode Kruis

patent

5. 1 out of 3

Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het

patents

where one patent can have more than one assignee

Years Active: 1999-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10906960 - Factor VIII variants having a decreased cellular uptake (2021-02-02),

2. 10047142 - Factor VIII variants having a decreased cellular uptake (2018-08-14),

3. 9321827 - Factor VIII variants having a decreased cellular uptake (2016-04-26),

4. 8586538 - Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII (2013-11-19),

5. 8546332 - Factor VIII polypeptide having factor VIII:C activity (2013-10-01),

6. 7544660 - Factor VIII polypeptide having factor VIII:C activity (2009-06-09),

7. 6919311 - Factor VII polypeptide having factor VII:C activity (2005-07-19),

8. 6284871 - Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation (2001-09-04),

9. 6083905 - Method and means for detecting and treating disorders in the blood (2000-07-04),

10. 5932706 - Antibodies specific for a haemostatic protein their use for isolating (1999-08-03),

Title: Koenraad Mertens: Innovator in Coagulation Factors

Introduction

Koenraad Mertens is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of coagulation factors, particularly through his innovative work on Factor VIII variants. With a total of 10 patents to his name, Mertens has established himself as a key figure in medical research and development.

Latest Patents

Mertens' latest patents focus on modified coagulation factors. One of his notable inventions is related to Factor VIII variants that have a decreased cellular uptake. This invention aims to improve the efficacy and safety of coagulation therapies. The modifications to Factor VIII molecules are designed to enhance their performance in clinical applications.

Career Highlights

Throughout his career, Mertens has worked with prominent organizations such as Stichting Sanquin Bloedvoorziening and the Sanquin Blood Supply Foundation. His work in these institutions has allowed him to advance research in blood coagulation and related therapies. His contributions have been instrumental in developing new treatment options for patients with bleeding disorders.

Collaborations

Mertens has collaborated with esteemed colleagues in his field, including Jan Aart Van Mourik and Petrus Johannes Lenting. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Koenraad Mertens is a distinguished inventor whose work on coagulation factors has had a significant impact on medical science. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.